Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A two-step temporal data augmentation and supervised learning framework for predicting autism diagnosis at 36 months in patients with tuberous sclerosis complex.

Computers in biology and medicine·2026
Same author

Tuberous sclerosis complex.

Nature reviews. Disease primers·2026
Same author

Early Vocal Development in Tuberous Sclerosis Complex Predicts Language but Not Autism Outcomes.

Pediatric neurology·2026
Same author

Convolutional neural networks for automatic tuber segmentation and quantification of tuber burden in tuberous sclerosis complex.

Epilepsia·2025
Same author

Electrical stimulation for the induction of seizures is safe, well-tolerated and high-yield in children with drug-resistant epilepsy.

Epilepsy & behavior : E&B·2025
Same author

Limited Utility for Head Ultrasounds in the Evaluation of Tuberous Sclerosis Complex.

Pediatric neurology·2025

Related Experiment Videos

Current management of tuberous sclerosis complex.

Darcy A Krueger1, David N Franz

  • 1Tuberous Sclerosis Clinic, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Paediatric Drugs
|August 30, 2008
PubMed
Summary

Tuberous sclerosis complex (TSC) causes epilepsy and organ disease. New mTOR inhibitor therapies show promise in treating TSC-related tumors and improving lung function.

Area of Science:

  • Neurology
  • Genetics
  • Oncology

Background:

  • Tuberous sclerosis complex (TSC) is a genetic disorder.
  • It affects multiple organs, including the brain, kidneys, and lungs.
  • TSC is a significant cause of epilepsy and autism.

Purpose of the Study:

  • To review current therapeutic recommendations for TSC manifestations.
  • To highlight recent advancements in TSC treatment.

Main Methods:

  • Review of current medical and surgical management guidelines for TSC.
  • Analysis of recent clinical trial data for mTOR inhibitors in TSC patients.

Main Results:

  • mTOR inhibitors have shown efficacy in regressing TSC-related tumors.

Related Experiment Videos

  • These inhibitors also demonstrate improvements in pulmonary function for TSC patients.

    • Conclusions:

    • Current therapies address neurologic, renal, and pulmonary aspects of TSC.
    • mTOR inhibitors represent a promising therapeutic avenue for managing TSC manifestations.